Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a clinical-stage biotech firm, is opening a Share Purchase Plan (SPP) for eligible shareholders, offering new shares at $0.19 each, aiming to raise an additional $2 million following a $10 million placement to investors. The funds will support the upcoming Phase 2/3 STRIKE study for Motor Neurone Disease, among other corporate activities. Shareholders can participate without incurring brokerage or transaction costs, with the SPP set to close on 19 July 2024.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
